A 68-year-old man was first diagnosed with metastatic KRAS wild-type rectal cancer at the age of 65 and was treated with FOLFOX plus bevacizumab for 5 months and upon progression was treated with FOLFIRI plus cetuximab for a subsequent 8 months. This evidence concerns the gene KRAS and rectal cancer.